Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05268718
Collaborator
(none)
20
1
3
35
0.6

Study Details

Study Description

Brief Summary

This clinical study was conducted to evaluate the efficacy and safety of gold-silver cuprous oxide composite nanogels combined with photothermal therapy system in the treatment of severe drug-resistant bacterial keratitis ineffective by traditional antibiotic treatment in human eyes, and to provide translational applications. Based on the clinical evidence, a more effective and safe innovative treatment plan for corneal diseases has been developed.

Condition or Disease Intervention/Treatment Phase
  • Drug: Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel
  • Drug: Voriconazole eye drops
  • Other: Normal saline
Early Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Gold-silver-cuprous Oxide (Au-Ag-Cu2O) Composite Nanogel Combined With Photothermal Therapy in the Treatment of Severe Drug-resistant Microbial Keratitis
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nanogel photothermal therapy

After the subjects were enrolled in the study, the eyes were coated with Au-Ag-Cu2O nano-gel once (the concentration was 26.4μg/mL, the dosage was suitable to cover the ulcer surface evenly, and the dosage was recorded). Combined with mdl-n-808-10w near-infrared laser (China changchun new industry photoelectric technology) combined with photothermal therapy (laser wavelength 808 nm, power 1.5W/cm2, temperature controlled at 40℃, lasting 10min)

Drug: Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel
Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
Other Names:
  • Au-Ag-Cu2O nano-gel
  • Active Comparator: Voriconazole eye drops

    Voliconazole eye drops (once in half an hour) were also used in the control group.

    Drug: Voriconazole eye drops
    Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
    Other Names:
  • VRC
  • Placebo Comparator: Normal saline

    Normal saline eye drops (once in half an hour) were also used in the control group.

    Other: Normal saline
    To be placebo, normal saline were administrated to infectious eye
    Other Names:
  • NS
  • Outcome Measures

    Primary Outcome Measures

    1. Anterior segment photography [1 month]

      corneal edema, keratohelcosis, hppopyon

    2. confocal microscopy [1 month]

      fungal hyphae in corneal surface

    Secondary Outcome Measures

    1. eye pressure [1 month]

      Measurement of contact tonometry with iCare TA01i tonometer after treatment (1 day, 1 week, 1 month)

    2. visual acuity [1 month]

      Measurement of distance visual acuity with subjective refraction after treatment (1 week, 1 month)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. The monocular cases of severe infectious keratitis admitted to our center were diagnosed as fungal keratitis according to their medical history, physical signs and surface secretions smear examination of corneal ulcer lesions (severe was defined as subjects with visual acuity < 0.15, deep stromal infiltration or involvement diameter

    2mm, with extensive infiltration around or with extensive suppuration)

    1. After more than 2 weeks of active treatment with antibiotics, there was no effect

    2. The researchers communicated with the subjects in detail, and the subjects cooperated well and they voluntarily participated and signed informed consent

    Exclusion Criteria:
    1. Allergic to the drug in this test.

    2. Pregnant and lactating women.

    3. The medical history suggests serious heart, lung, liver, kidney dysfunction.

    4. Patients with other factors that would affect the results of this result.

    5. No signed informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China 310009

    Sponsors and Collaborators

    • Second Affiliated Hospital, School of Medicine, Zhejiang University

    Investigators

    • Study Director: Ke Yao, MD, Second Affiliated Hospital of Zhejiang University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Second Affiliated Hospital, School of Medicine, Zhejiang University
    ClinicalTrials.gov Identifier:
    NCT05268718
    Other Study ID Numbers:
    • 2021-0635
    First Posted:
    Mar 7, 2022
    Last Update Posted:
    Mar 7, 2022
    Last Verified:
    Aug 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Second Affiliated Hospital, School of Medicine, Zhejiang University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 7, 2022